Posters

      A One-month Study to Evaluate Biomarkers of Exposure and Effect in Smokers Switching from Conventional Cigarettes to an Electrically Heated Cigarette Smoking System

      Martin Leroy, C.; Jarus-Dziedzic, K.; Ancerewicz, J. Ancerewicz.; Bentley, M.; Lindner, D.; Magnette, J.; Browne, H.

      Conference date
      Apr 27, 2009
      Conference name
      Society for Research on Nicotine and Tobacco (SRNT) 2009
      Link to more information
      Link to more information
      Topic
      Summary

      Previous studies have demonstrated reductions in exposure to selected smoke constituents in smokers who switch from conventional cigarettes (CC) to an electrically heated cigarette smoking system (K6) under controlled smoking conditions. The aim of this study was to make a preliminary investigation of changes in a variety of candidate biomarkers of effect (BoEff) and exposure (BoExp) in subjects after smoking K6 cigarettes for one month under real-life conditions. This clinical investigation was a single-centre, randomised, open-label, two-arm study. Caucasian smokers aged from 30 to 60 years were enrolled and randomised to one of two groups: those who would continue to smoke conventional cigarettes (CC) and those who would switch to smoking the K6 cigarette for one month. A selection of BoExp and BoEff in blood and urine were compared between study groups at study end. This study was conducted in Poland from October 2007 to April 2008 in accordance with the principles of good clinical practice. A total of 338 subjects were enrolled, of which 316 were randomised to either the CC study arm (n=79) or to the K6 study arm (n=237). A number of BoExp for smoke constituents were measured in this study.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.